How to Get Evenity (Romosozumab) in Colorado

Who Qualifies for Romosozumab in Colorado

Evenity is FDA-approved for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple fracture risk factors, or failure of other osteoporosis therapies [1]. The FDA prescribing information carries a boxed warning for increased cardiovascular risk, specifically myocardial infarction, stroke, and cardiovascular death.

In the ARCH trial (N=4,093), romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months, with a 27% lower risk of clinical fractures [2]. These data established romosozumab as the most potent anabolic bone agent available. Colorado providers use FRAX scores, DXA T-scores of -2.5 or below, and prior fracture history to determine eligibility. Patients who have failed bisphosphonates or denosumab are strong candidates.

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend romosozumab as first-line therapy for patients at "very high" fracture risk, defined as a T-score of -3.0 or lower, recent fractures within 12 months, or fractures while on approved osteoporosis therapy [3].

Telehealth Access for Evenity in Colorado

Yes, Colorado law permits telehealth prescribing of romosozumab. Colorado's telehealth parity statute (SB 20-212) requires insurers to cover telehealth services at the same reimbursement rate as in-person visits, and the state does not restrict which medications can be prescribed via telemedicine as long as the provider-patient relationship is established [4].

A telehealth consultation for Evenity typically includes a review of DXA scan results, fracture history, cardiovascular screening, and baseline labs. The provider can submit prior authorization electronically and coordinate with a specialty pharmacy for delivery. Most telehealth visits for osteoporosis evaluation last 20 to 30 minutes.

Colorado-based endocrinologists and rheumatologists who practice via telehealth platforms can prescribe Evenity to patients anywhere in the state. Patients in rural counties like Moffat, San Juan, or Dolores, where bone density specialists are scarce, benefit most from this access pathway. The injection itself is administered at home or in a provider's office.

Required Labs Before Starting Evenity

Providers in Colorado must obtain specific laboratory values before initiating romosozumab. Hypocalcemia must be corrected prior to treatment. The required baseline panel includes serum calcium (corrected for albumin), 25-hydroxyvitamin D, and a comprehensive metabolic panel to assess renal function [1].

The Endocrine Society clinical practice guidelines recommend a minimum 25-hydroxyvitamin D level of 30 ng/mL before starting any anabolic bone therapy [5]. Patients below this threshold receive high-dose ergocalciferol (50 to 000 IU weekly for 8 weeks) before romosozumab initiation. A repeat level confirms repletion.

Additional cardiovascular screening is required given the FDA boxed warning. Providers assess 10-year ASCVD risk using the Pooled Cohort Equations. Patients with a history of myocardial infarction or stroke within the prior year are excluded. An ECG is not mandated by the label but is commonly ordered in patients over 65 with multiple cardiovascular risk factors.

Bone turnover markers (P1NP, CTX) are optional but useful for monitoring treatment response. P1NP peaks at month one of romosozumab therapy and returns to baseline by month 12, confirming the drug's time-limited anabolic window [6].

Prior Authorization Requirements in Colorado

Nearly all commercial insurers in Colorado require prior authorization for Evenity. The process demands clinical documentation proving the patient meets specific criteria. Here is what Colorado insurers typically require:

Documentation for prior authorization includes a DXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip. Insurers also request evidence of at least one of the following: a prior osteoporotic fracture, failure or intolerance of oral bisphosphonates (typically 12 months of alendronate or risedronate), or a FRAX 10-year major osteoporotic fracture probability exceeding 20%.

The prescriber must attest that the patient has no contraindications, including no MI or stroke in the preceding 12 months, and that serum calcium is within normal limits. Turnaround time for prior authorization decisions in Colorado ranges from 48 hours to 14 business days depending on the insurer. Anthem Blue Cross Blue Shield of Colorado, Cigna, and UnitedHealthcare each maintain specific step-therapy requirements.

Colorado Medicaid (Health First Colorado) does not cover Evenity for osteoporosis as of 2026. Coverage is restricted to type 2 diabetes indications only. Patients on Medicaid may appeal through the Colorado Department of Health Care Policy and Financing, though approval rates for off-formulary osteoporosis agents remain low. Medicare Part B covers Evenity when administered in a provider's office, with the patient responsible for the 20% coinsurance.

Which Providers Can Prescribe Evenity in Colorado

In Colorado, any provider with independent prescriptive authority can prescribe romosozumab. This includes physicians (MD and DO), nurse practitioners (NP), and physician assistants (PA). Colorado grants NPs full practice authority without physician oversight, per Colorado Revised Statutes § 12-255-112.

Endocrinologists, rheumatologists, and orthopedic surgeons prescribe Evenity most frequently. Primary care physicians can also prescribe it, though many refer to specialists given the prior authorization complexity and cardiovascular monitoring requirements. The Colorado Medical Society lists approximately 180 board-certified endocrinologists practicing statewide.

For telehealth prescribing, the provider must hold an active Colorado medical license. Out-of-state providers can obtain a Colorado license through the Interstate Medical Licensure Compact, of which Colorado is a member state. This enables patients to access osteoporosis specialists who are physically located elsewhere but licensed in Colorado.

Pharmacy Access and Specialty Distribution

Evenity is classified as a specialty medication and is distributed through specialty pharmacies rather than retail pharmacies. In Colorado, major specialty pharmacy options include Optum Specialty Pharmacy, CVS Specialty, Accredo (Express Scripts), and AllianceRx Walgreens Prime. These pharmacies handle cold-chain shipping, patient onboarding, and insurance coordination.

Colorado's 503A compounding pharmacies are licensed to dispense specialty biologics when operating under a valid prescription, though romosozumab itself is a patented biologic not typically compounded. The 503A designation becomes relevant for adjunctive therapies like calcium citrate preparations or vitamin D formulations that a provider may co-prescribe.

Evenity is supplied as two prefilled syringes (105 mg each) administered together for a total dose of 210 mg. The medication requires refrigeration at 2°C to 8°C. Specialty pharmacies ship with cold packs and temperature monitors. Patients in Colorado typically receive their monthly shipment 3 to 5 business days after the pharmacy confirms insurance authorization.

The wholesale acquisition cost (WAC) for Evenity is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course [7]. With insurance, patient out-of-pocket costs vary. Amgen's Evenity Co-pay Card program reduces commercially insured patients' costs to as little as $5 per month for eligible individuals.

Timeline from Consultation to First Injection

The typical timeline from initial consultation to first Evenity injection in Colorado spans 2 to 6 weeks. That breaks down as follows: telehealth or in-person evaluation (day 1), lab draw and results (days 2 to 5), prior authorization submission (days 5 to 7), insurer decision (days 7 to 21), specialty pharmacy processing and shipping (days 21 to 28), and first injection (days 28 to 42).

Delays occur most often at the prior authorization stage. If denied, the prescriber files a peer-to-peer review or formal appeal. Colorado insurance regulations require insurers to respond to urgent prior authorization requests within 24 hours and standard requests within 10 business days per Colorado Division of Insurance rules [8].

Patients who self-pay or use manufacturer assistance programs bypass insurance timelines entirely. In these cases, the specialty pharmacy can ship within 5 to 7 business days of receiving the prescription.

Cardiovascular Safety Monitoring During Treatment

The ARCH trial reported a higher incidence of major adverse cardiac events (MACE) in the romosozumab group compared to alendronate: 2.5% versus 1.9% over 12 months of treatment [2]. The absolute risk difference was 0.6%, and the FDA mandated the boxed warning based on these findings.

Colorado providers follow a monitoring protocol that includes blood pressure assessment at each monthly injection visit, inquiry about new chest pain or neurological symptoms, and repeat cardiovascular risk assessment at month 6. The AACE guidelines recommend against prescribing romosozumab to patients with recent (within 12 months) cardiovascular events or those at very high cardiovascular risk without a risk-benefit discussion [3].

After completing 12 months of romosozumab, patients must transition to an antiresorptive agent (typically denosumab or a bisphosphonate) to maintain bone density gains. Failure to sequence therapy results in rapid bone loss. The FRAME extension study showed that patients who received denosumab after romosozumab gained an additional 3.5% BMD at the lumbar spine over the following 12 months [9].

Cost Assistance and Insurance Navigation for Colorado Patients

For commercially insured patients, Amgen's Evenity Together program provides co-pay assistance reducing monthly costs to $5 for eligible patients. The program covers up to $15,000 annually in co-pay expenses. Patients must have commercial insurance; those on Medicare, Medicaid, or other government programs are ineligible for manufacturer co-pay cards.

Colorado patients without adequate insurance can explore the Amgen Safety Net Foundation, which provides Evenity at no cost to qualifying patients with household incomes at or below 400% of the federal poverty level. Application requires proof of income, insurance status, and a valid prescription.

Medicare Part B covers Evenity when administered as an incident-to service in a physician's office. The patient owes 20% coinsurance after meeting their Part B deductible ($257 in 2026). For a $1,825 monthly dose, that equals approximately $365 per injection without supplemental coverage. Medigap plans (particularly Plan G and Plan N) cover the remaining coinsurance.

Colorado's Senior Health Insurance Assistance Program (SHIP) provides free counseling to Medicare beneficiaries navigating specialty drug coverage. Patients can call 303-894-7499 or visit any county Area Agency on Aging office for one-on-one prior authorization and appeals guidance.

Transitioning After 12 Months of Romosozumab

Romosozumab's anabolic effect is time-limited. Sclerostin antibody action peaks during months 1 through 6, and modeling-based bone formation returns to baseline by month 12 [6]. Continuing beyond 12 doses provides no additional benefit and is not FDA-approved.

The mandatory transition to antiresorptive therapy is the most clinically significant decision point in the treatment course. Data from the FRAME trial extension demonstrate that romosozumab followed by denosumab produced a total hip BMD increase of 7.1% over 24 months, compared to 4.4% with placebo followed by denosumab [9]. Colorado providers typically prescribe denosumab 60 mg subcutaneously every 6 months as the sequencing agent, given its efficacy in maintaining romosozumab-induced gains.

Patients who cannot tolerate denosumab or prefer oral therapy may transition to zoledronic acid 5 mg IV annually or oral alendronate 70 mg weekly. The choice depends on renal function, GI tolerance, and patient preference. Labs at month 12 should include repeat DXA (to document treatment response), serum calcium, and CTX to confirm bone turnover suppression before switching agents.